Inosine

Identification

Summary

Inosine is a nutritional supplement touted to improve athletic performance and a drug used in vitro as a red blood cell rejuvenator for a unit of red blood cells that will be used in a clinical setting.

Brand Names
Rejuvesol
Generic Name
Inosine
DrugBank Accession Number
DB04335
Background

A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)

Type
Small Molecule
Groups
Experimental, Investigational
Structure
Weight
Average: 268.2261
Monoisotopic: 268.080769514
Chemical Formula
C10H12N4O5
Synonyms
  • 9-β-D-ribofuranosyl-9H-purin-6-ol
  • 9-β-D-ribofuranosylhypoxanthine
  • beta-Inosine
  • hypoxanthine D-riboside
  • Hypoxanthosine
  • INO
  • Inosin
  • Inosina
  • Inosine
  • Inosinum

Pharmacology

Indication

The primary popular claim made for inosine, that it enhances exercise and athletic performance, is refuted by the available research data. There is some preliminary evidence that inosine may have some neurorestorative, anti-inflammatory, immunomodulatory and cardioprotective effects.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Inosine may have neuroprotective, cardioprotective, anti-inflammatory and immunomodulatory activities.

Mechanism of action

Inosine has been found to have potent axon-promoting effects in vivo following unilateral transection of the corticospinal tract of rats. The mechanism of this action is unclear. Possibilities include serving as an agonist of a nerve growth factor-activated protein kinase (N-Kinase), conversion to cyclic nucleotides that enable advancing nerve endings to overcome the inhibitory effects of myelin, stimulation of differentiation in rat sympathetic neurons, augmentation of nerve growth factor-induced neuritogenesis and promotion of the survival of astrocytes, among others. The mechanism of inosine's possible cardioprotective effect is similarly unclear. Inosine has been reported to have a positive inotropic effect and also to have mild coronary vasodilation activity. Exogenous inosine may contribute to the high-energy phosphate pool of cardiac muscle cells and favorably affect bioenergetics generally. Inosine has also been reported to enhance the myocardial uptake of carbohydrates relative to free fatty acids as well as glycolysis. In cell culture studies, inosine has been found to inhibit the production, in immunostimulated macrophages and spleen cells, of the proinflammatory cytokines, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1, interleukin (IL)-12, macrophage-inflammatory protein-1 alpha and interferon (IFN)-gamma. It also suppressed proinflammatory cytokine production and mortality in a mouse endotoxemic model. These actions might account for the possible immunomodulatory, anti-inflammatory and anti-ischemic actions of inosine.

TargetActionsOrganism
UPurine nucleoside phosphorylaseNot AvailableHumans
UIAG-nucleoside hydrolaseNot AvailableTrypanosoma vivax
UPurine nucleoside phosphorylase DeoD-typeNot AvailableEscherichia coli (strain K12)
Absorption

Ingested inosine is absorbed from the small intestine.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

In the liver, inosine may be catabolized by a series of reactions culminating in the production of uric acid and also may be metabolized to adenine- and guanine-containing nucleotides. Inosine not metabolized in the liver is transported via the systemic circulation and distributed to various tissues of the body, where it is metabolized in similar fashion as in the liver. Uric acid, the purine end-product of inosine catabolism, is excreted in the urine.

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
PathwayCategory
Adenylosuccinate Lyase DeficiencyDisease
Xanthine Dehydrogenase Deficiency (Xanthinuria)Disease
Xanthinuria Type IDisease
Mitochondrial DNA Depletion SyndromeDisease
Myoadenylate Deaminase DeficiencyDisease
Purine MetabolismMetabolic
Purine Nucleoside Phosphorylase DeficiencyDisease
Lesch-Nyhan Syndrome (LNS)Disease
Gout or Kelley-Seegmiller SyndromeDisease
Mercaptopurine Action PathwayDrug action
Adenine Phosphoribosyltransferase Deficiency (APRT)Disease
Adenosine Deaminase DeficiencyDisease
AICA-RibosiduriaDisease
Molybdenum Cofactor DeficiencyDisease
Azathioprine Action PathwayDrug action
Thioguanine Action PathwayDrug action
Xanthinuria Type IIDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Catacol (Alcon) / Inotin / Lumiclar (Valeant)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
RejuvesolInosine (1.34 g/50mL) + Adenine (0.034 g/50mL) + Sodium pyruvate (0.55 g/50mL) + Sodium phosphate, dibasic, unspecified form (0.73 g/50mL) + Sodium phosphate, monobasic, monohydrate (0.311 g/50mL)SolutionExtracorporealCitra Labs, LLC1997-02-26Not applicableUS flag

Categories

ATC Codes
G01AX02 — InosineS01XA10 — InosineD06BB05 — Inosine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleosides
Sub Class
Not Available
Direct Parent
Purine nucleosides
Alternative Parents
Glycosylamines / 6-oxopurines / Pentoses / Hypoxanthines / Pyrimidones / N-substituted imidazoles / Vinylogous amides / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols
show 7 more
Substituents
6-oxopurine / Alcohol / Aromatic heteropolycyclic compound / Azacycle / Azole / Glycosyl compound / Heteroaromatic compound / Hydrocarbon derivative / Hypoxanthine / Imidazole
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
inosines (CHEBI:17596)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
5A614L51CT
CAS number
58-63-9
InChI Key
UGQMRVRMYYASKQ-KQYNXXCUSA-N
InChI
InChI=1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1
IUPAC Name
9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3H-purin-6-one
SMILES
OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O

References

Synthesis Reference

U.S. Patent 3,049,536 U.S. Patent 3,111,459

General References
Not Available
Human Metabolome Database
HMDB0000195
KEGG Drug
D00054
KEGG Compound
C00294
PubChem Compound
6021
PubChem Substance
175426857
ChemSpider
5799
BindingDB
22104
RxNav
1483575
ChEBI
17596
ChEMBL
CHEMBL1556
ZINC
ZINC000008855117
PharmGKB
PA130230922
PDBe Ligand
NOS
PDRhealth
PDRhealth Drug Page
Wikipedia
Inosine
PDB Entries
1a9s / 1kic / 1pr0 / 1rct / 1z38 / 2bsx / 2fqw / 3b1p / 3b1q / 3b9x
show 13 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedOtherSickle Cell Disease (SCD)1
4WithdrawnBasic ScienceHeart Defects,Congenital1
3CompletedOtherParkinson's Disease (PD)1
3CompletedTreatmentCognitive Dysfunctions1
3CompletedTreatmentDiabetic Neuropathies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionExtracorporeal
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)218 dec °CPhysProp
water solubility1.58E+004 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-2.10HANSCH,C ET AL. (1995)
logS-1.23ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility14.3 mg/mLALOGPS
logP-1.7ALOGPS
logP-2Chemaxon
logS-1.3ALOGPS
pKa (Strongest Acidic)10.93Chemaxon
pKa (Strongest Basic)2.74Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area129.2 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity60.9 m3·mol-1Chemaxon
Polarizability24.6 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9523
Blood Brain Barrier+0.7979
Caco-2 permeable-0.907
P-glycoprotein substrateNon-substrate0.6601
P-glycoprotein inhibitor INon-inhibitor0.9717
P-glycoprotein inhibitor IINon-inhibitor0.8979
Renal organic cation transporterNon-inhibitor0.9422
CYP450 2C9 substrateNon-substrate0.8063
CYP450 2D6 substrateNon-substrate0.8396
CYP450 3A4 substrateNon-substrate0.558
CYP450 1A2 substrateNon-inhibitor0.8425
CYP450 2C9 inhibitorNon-inhibitor0.9637
CYP450 2D6 inhibitorNon-inhibitor0.9629
CYP450 2C19 inhibitorNon-inhibitor0.9607
CYP450 3A4 inhibitorNon-inhibitor0.9825
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.954
Ames testNon AMES toxic0.9354
CarcinogenicityNon-carcinogens0.922
BiodegradationNot ready biodegradable0.7774
Rat acute toxicity2.0115 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9855
hERG inhibition (predictor II)Non-inhibitor0.908
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-0frt-0890000000-c0c5ebc2bbf12c1a7edf
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)GC-MSsplash10-00di-9440000000-566aadb777ee03fb22fb
GC-MS Spectrum - GC-MS (4 TMS)GC-MSsplash10-0fsi-1690000000-364bf8794afeeff6ba51
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0adl-9250000000-d6ee10ae0804bda3e4ce
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0frt-0890000000-c0c5ebc2bbf12c1a7edf
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00di-9440000000-566aadb777ee03fb22fb
GC-MS Spectrum - GC-MSGC-MSsplash10-0fsi-1690000000-364bf8794afeeff6ba51
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-000i-0900000000-012b2024bf3b3837c54c
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-000i-0900000000-08a2204bd9dd4d300b73
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-000i-2900000000-8da9aa27b202f672fb83
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-001i-0930000000-ee37a7516ef378cd665d
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-014i-0900000000-e0575da4ae91163a2a90
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-000i-0900000000-379f5383e1bd290db9b6
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-0udi-0900000000-cd539725f09d01a39e25
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-0uxr-0930000000-b69310182305cd88dbc5
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-00l2-9300000000-65a24aadb3a2b262cacf
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-001i-0900000000-9c77149cd916c0340573
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-000i-0900000000-e8f9aac2c9bfc820dc7d
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-014r-0490020000-6eeacbf0ca8726ed8542
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0006-9100000000-cdcc2e477ba37ca8f07a
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-001i-0900000000-f96733a8f63a90d3644d
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0002-0900000000-b9b05cbee9a42ce87c0f
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-015i-0696011000-c836d8cd13395c898ae1
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0006-9100000000-d8c6fdb9231ac2c6e939
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-001i-0900000000-632ba91cd477e5aaf9e5
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-001i-0910000000-fc11279b73334e4ea0a8
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-014i-0090000000-00981efb4a9571473866
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-014i-0390000000-989ff580a7b60b151996
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-000i-0920000000-b78cba83cbf8f1ae48f3
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-000i-0910000000-505a6507fcb525fe9a14
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-052r-2900000000-33d1372d34f6b06e3a2f
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , PositiveLC-MS/MSsplash10-000i-0900000000-a0601a44cbbc12888cc2
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) 30V, PositiveLC-MS/MSsplash10-000i-0900000000-650dd5a1118bbbfcf6bf
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , NegativeLC-MS/MSsplash10-000i-0930000000-9285a36e16cdf00b3f71
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-0090000000-00981efb4a9571473866
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-0390000000-989ff580a7b60b151996
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-0920000000-b78cba83cbf8f1ae48f3
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-0910000000-c6d9b3470f4bf20f2031
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-052r-2900000000-33d1372d34f6b06e3a2f
LC-MS/MS Spectrum - LC-ESI-IT , negativeLC-MS/MSsplash10-000i-0900000000-cb192ec0941c4e4f04b1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-9100000000-1b4c3c2319fbba7de36b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-0900000000-cc8e5ee2239e2de92705
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-9100000000-d8c6fdb9231ac2c6e939
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-0900000000-632ba91cd477e5aaf9e5
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-000i-0930000000-6d3be934cd4b9ed750dd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-379f5383e1bd290db9b6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00l2-9300000000-65a24aadb3a2b262cacf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-e8f9aac2c9bfc820dc7d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-a0601a44cbbc12888cc2
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-650dd5a1118bbbfcf6bf
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0490000000-61c2677e7a4ab4f4c864
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-1790000000-c57b67e8d19985858053
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0910000000-55e443e480d67bbdccaa
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0900000000-2e4f2f0b956041b7c4f1
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-3900000000-b9669596cd5e35383595
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0900000000-70b710b006170929b4d0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0910000000-116a8d85053da739f5b6
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0920000000-2b8a9bb94021f1e3440b
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0900000000-c1d7e96a44d7eb10c39c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-052u-5900000000-3b49fc80a294620bd395
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-4900000000-48c6d88284c76c94108f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4u-3900000000-191a6dcebc20da701a0d
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
[1H,1H] 2D NMR Spectrum2D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-169.0414332
predicted
DarkChem Lite v0.1.0
[M-H]-167.9155332
predicted
DarkChem Lite v0.1.0
[M-H]-168.9635332
predicted
DarkChem Lite v0.1.0
[M-H]-149.04985
predicted
DeepCCS 1.0 (2019)
[M-H]-169.0414332
predicted
DarkChem Lite v0.1.0
[M-H]-167.9155332
predicted
DarkChem Lite v0.1.0
[M-H]-168.9635332
predicted
DarkChem Lite v0.1.0
[M-H]-149.04985
predicted
DeepCCS 1.0 (2019)
[M+H]+169.7581332
predicted
DarkChem Lite v0.1.0
[M+H]+168.6665332
predicted
DarkChem Lite v0.1.0
[M+H]+169.7317332
predicted
DarkChem Lite v0.1.0
[M+H]+151.44542
predicted
DeepCCS 1.0 (2019)
[M+H]+169.7581332
predicted
DarkChem Lite v0.1.0
[M+H]+168.6665332
predicted
DarkChem Lite v0.1.0
[M+H]+169.7317332
predicted
DarkChem Lite v0.1.0
[M+H]+151.44542
predicted
DeepCCS 1.0 (2019)
[M+Na]+169.1629332
predicted
DarkChem Lite v0.1.0
[M+Na]+168.3755332
predicted
DarkChem Lite v0.1.0
[M+Na]+169.6233332
predicted
DarkChem Lite v0.1.0
[M+Na]+158.05357
predicted
DeepCCS 1.0 (2019)
[M+Na]+169.1629332
predicted
DarkChem Lite v0.1.0
[M+Na]+168.3755332
predicted
DarkChem Lite v0.1.0
[M+Na]+169.6233332
predicted
DarkChem Lite v0.1.0
[M+Na]+158.05357
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Purine-nucleoside phosphorylase activity
Specific Function
The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine ...
Gene Name
PNP
Uniprot ID
P00491
Uniprot Name
Purine nucleoside phosphorylase
Molecular Weight
32117.69 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Kind
Protein
Organism
Trypanosoma vivax
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
Q9GPQ4
Uniprot Name
IAG-nucleoside hydrolase
Molecular Weight
36330.44 Da
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Purine-nucleoside phosphorylase activity
Specific Function
Cleavage of guanosine or inosine to respective bases and sugar-1-phosphate molecules.
Gene Name
deoD
Uniprot ID
P0ABP8
Uniprot Name
Purine nucleoside phosphorylase DeoD-type
Molecular Weight
25949.68 Da

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Xanthine oxidase activity
Specific Function
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Ha...
Gene Name
XDH
Uniprot ID
P47989
Uniprot Name
Xanthine dehydrogenase/oxidase
Molecular Weight
146422.99 Da
References
  1. STIRPE F, DELLACORTE E: REGULATION OF XANTHINE DEHYDROGENASE IN CHICK LIVER. EFFECT OF STARVATION AND OF ADMINISTRATION OF PURINES AND PURINE NUCLEOSIDES. Biochem J. 1965 Feb;94:309-13. [Article]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Pyrimidine- and adenine-specific:sodium symporter activity
Specific Function
Sodium-dependent, pyrimidine- and purine-selective. Involved in the homeostasis of endogenous nucleosides. Exhibits the transport characteristics of the nucleoside transport system cib or N3 subtyp...
Gene Name
SLC28A3
Uniprot ID
Q9HAS3
Uniprot Name
Solute carrier family 28 member 3
Molecular Weight
76929.61 Da
References
  1. Badagnani I, Chan W, Castro RA, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, Burchard EG, Giacomini KM: Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J. 2005;5(3):157-65. [Article]

Drug created at June 13, 2005 13:24 / Updated at September 28, 2021 21:54